Platelet transfusion therapy in acute leukemia: Lack of effect of splenomegaly on transfusion requirements and risk of hemorrhage

Thomas Elmer Witzig, B. S. Ducatman, M. R. Wick, L. Letendre, S. B. Moore, D. M. Ilstrup, H. F. Taswell

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Platelet transfusions are an important supportive measure during treatment for acute nonlymphocytic leukemia (ANLL). The presence of splenomegaly may produce decreased posttransfusion platelet increments leading some to recommend an increased dose of platelets per transfusion in this situation. Forty-nine newly diagnosed patients with ANLL were evaluated during 1980 and 1981, and 24% had palpable splenomegaly. Although treated with usual doses of platelets per transfusion, there was no detectable statistical increase in transfusion requirement or incidence of hemorrhage in patients with splenomegaly. Experimental evidence indicates that the splenic platelet pool enlarges with splenomegaly, but the life span of circulating platelets is not significantly changed. Furthermore, the splenic platelet pool is in dynamic equilibrium with the circulating pool thus allowing these platelets to participate in hemostasis. Although posttransfusion increment in platelet count may be less, it appears that platelet transfusion therapy need not be altered solely because of splenomegaly.

Original languageEnglish (US)
Pages (from-to)345-350
Number of pages6
JournalAmerican Journal of Hematology
Volume18
Issue number4
DOIs
StatePublished - 1985

Fingerprint

Platelet Transfusion
Splenomegaly
Leukemia
Blood Platelets
Hemorrhage
Acute Myeloid Leukemia
Therapeutics
Hemostasis
Platelet Count
Incidence

ASJC Scopus subject areas

  • Hematology

Cite this

Platelet transfusion therapy in acute leukemia : Lack of effect of splenomegaly on transfusion requirements and risk of hemorrhage. / Witzig, Thomas Elmer; Ducatman, B. S.; Wick, M. R.; Letendre, L.; Moore, S. B.; Ilstrup, D. M.; Taswell, H. F.

In: American Journal of Hematology, Vol. 18, No. 4, 1985, p. 345-350.

Research output: Contribution to journalArticle

Witzig, Thomas Elmer ; Ducatman, B. S. ; Wick, M. R. ; Letendre, L. ; Moore, S. B. ; Ilstrup, D. M. ; Taswell, H. F. / Platelet transfusion therapy in acute leukemia : Lack of effect of splenomegaly on transfusion requirements and risk of hemorrhage. In: American Journal of Hematology. 1985 ; Vol. 18, No. 4. pp. 345-350.
@article{4b349e7412234137b78f9c9a2bc9db2a,
title = "Platelet transfusion therapy in acute leukemia: Lack of effect of splenomegaly on transfusion requirements and risk of hemorrhage",
abstract = "Platelet transfusions are an important supportive measure during treatment for acute nonlymphocytic leukemia (ANLL). The presence of splenomegaly may produce decreased posttransfusion platelet increments leading some to recommend an increased dose of platelets per transfusion in this situation. Forty-nine newly diagnosed patients with ANLL were evaluated during 1980 and 1981, and 24{\%} had palpable splenomegaly. Although treated with usual doses of platelets per transfusion, there was no detectable statistical increase in transfusion requirement or incidence of hemorrhage in patients with splenomegaly. Experimental evidence indicates that the splenic platelet pool enlarges with splenomegaly, but the life span of circulating platelets is not significantly changed. Furthermore, the splenic platelet pool is in dynamic equilibrium with the circulating pool thus allowing these platelets to participate in hemostasis. Although posttransfusion increment in platelet count may be less, it appears that platelet transfusion therapy need not be altered solely because of splenomegaly.",
author = "Witzig, {Thomas Elmer} and Ducatman, {B. S.} and Wick, {M. R.} and L. Letendre and Moore, {S. B.} and Ilstrup, {D. M.} and Taswell, {H. F.}",
year = "1985",
doi = "10.1002/ajh.2830180403",
language = "English (US)",
volume = "18",
pages = "345--350",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Platelet transfusion therapy in acute leukemia

T2 - Lack of effect of splenomegaly on transfusion requirements and risk of hemorrhage

AU - Witzig, Thomas Elmer

AU - Ducatman, B. S.

AU - Wick, M. R.

AU - Letendre, L.

AU - Moore, S. B.

AU - Ilstrup, D. M.

AU - Taswell, H. F.

PY - 1985

Y1 - 1985

N2 - Platelet transfusions are an important supportive measure during treatment for acute nonlymphocytic leukemia (ANLL). The presence of splenomegaly may produce decreased posttransfusion platelet increments leading some to recommend an increased dose of platelets per transfusion in this situation. Forty-nine newly diagnosed patients with ANLL were evaluated during 1980 and 1981, and 24% had palpable splenomegaly. Although treated with usual doses of platelets per transfusion, there was no detectable statistical increase in transfusion requirement or incidence of hemorrhage in patients with splenomegaly. Experimental evidence indicates that the splenic platelet pool enlarges with splenomegaly, but the life span of circulating platelets is not significantly changed. Furthermore, the splenic platelet pool is in dynamic equilibrium with the circulating pool thus allowing these platelets to participate in hemostasis. Although posttransfusion increment in platelet count may be less, it appears that platelet transfusion therapy need not be altered solely because of splenomegaly.

AB - Platelet transfusions are an important supportive measure during treatment for acute nonlymphocytic leukemia (ANLL). The presence of splenomegaly may produce decreased posttransfusion platelet increments leading some to recommend an increased dose of platelets per transfusion in this situation. Forty-nine newly diagnosed patients with ANLL were evaluated during 1980 and 1981, and 24% had palpable splenomegaly. Although treated with usual doses of platelets per transfusion, there was no detectable statistical increase in transfusion requirement or incidence of hemorrhage in patients with splenomegaly. Experimental evidence indicates that the splenic platelet pool enlarges with splenomegaly, but the life span of circulating platelets is not significantly changed. Furthermore, the splenic platelet pool is in dynamic equilibrium with the circulating pool thus allowing these platelets to participate in hemostasis. Although posttransfusion increment in platelet count may be less, it appears that platelet transfusion therapy need not be altered solely because of splenomegaly.

UR - http://www.scopus.com/inward/record.url?scp=0021906724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021906724&partnerID=8YFLogxK

U2 - 10.1002/ajh.2830180403

DO - 10.1002/ajh.2830180403

M3 - Article

C2 - 3976647

AN - SCOPUS:0021906724

VL - 18

SP - 345

EP - 350

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -